Last reviewed · How we verify
Tapentadol Prolonged Release with Pregabalin
Tapentadol Prolonged Release with Pregabalin is a Small molecule drug developed by Grünenthal GmbH. It is currently FDA-approved.
At a glance
| Generic name | Tapentadol Prolonged Release with Pregabalin |
|---|---|
| Sponsor | Grünenthal GmbH |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tapentadol Prolonged Release with Pregabalin CI brief — competitive landscape report
- Tapentadol Prolonged Release with Pregabalin updates RSS · CI watch RSS
- Grünenthal GmbH portfolio CI
Frequently asked questions about Tapentadol Prolonged Release with Pregabalin
What is Tapentadol Prolonged Release with Pregabalin?
Tapentadol Prolonged Release with Pregabalin is a Small molecule drug developed by Grünenthal GmbH.
Who makes Tapentadol Prolonged Release with Pregabalin?
Tapentadol Prolonged Release with Pregabalin is developed and marketed by Grünenthal GmbH (see full Grünenthal GmbH pipeline at /company/gr-nenthal-gmbh).
What development phase is Tapentadol Prolonged Release with Pregabalin in?
Tapentadol Prolonged Release with Pregabalin is FDA-approved (marketed).